comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.
comirnaty konzentrat zur herstellung einer injektionsdispersion
pfizer ag - tozinameranum - konzentrat zur herstellung einer injektionsdispersion - tozinameranum 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas) pro dosi, 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, cholesterolum pro dosi, saccharum pro dosi, natrii chloridum pro dosi, natrii hydroxidum, dinatrii phosphas dihydricus pro dosi, kalii dihydrogenophosphas pro dosi, kalii chloridum pro dosi, acidum hydrochloridum, aqua ad iniectabile, natrium 0.16 mg et kalium 0.01 mg pro dosi. - comirnaty ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren - les vaccins
comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren
pfizer ag - tozinameranum, riltozinameranum - comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren - suspension: tozinameranum 15 µg pro dosi, riltozinameranum 15 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro dosi. - comirnaty original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 18 jahren - les vaccins
comirnaty original/omicron ba. 4-5 0.225 mg injektionsdispersion
pfizer ag - tozinameranum, famtozinameranum - injektionsdispersion - suspension: tozinameranum 0.05 mg/ml, famtozinameranum 0.05 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - comirnaty original/omicron ba.4-5 15/15 mikrogramm pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren. - les vaccins
comirnaty® 30 mikrogramm/dosis gebrauchsfertige injektionsdispersion für personen ab 12 jahren
pfizer ag - tozinameranum - gebrauchsfertige injektionsdispersion für personen ab 12 jahren - suspension: tozinameranum 0.1 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro praeparatione. - les vaccins
comirnaty® 10 mikrogramm/dosis konzentrat zur herstellung einer injektionsdispersion
pfizer ag - tozinameranum - konzentrat zur herstellung einer injektionsdispersion - suspension: tozinameranum 0.1 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - les vaccins
comirnaty omicron xbb.1.5 (30 mikrogramm)/dosis injektionsdispersion
pfizer ag - raxtozinameranum - injektionsdispersion - suspension: raxtozinameranum 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - comirnaty omicron xbb.1.5 (30 mikrogramm)/dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren - les vaccins
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccins - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 et 5. 1 in product information document). l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.
comirnaty original & omicron ba.4/ba.5 suspension
biontech manufacturing gmbh - tozinaméran; famtozinamÉran - suspension - 15mcg; 15mcg - tozinaméran 15mcg; famtozinamÉran 15mcg
comirnaty original/omicron ba.1 suspension
biontech manufacturing gmbh - tozinaméran; riltozinamÉran - suspension - 15mcg; 15mcg - tozinaméran 15mcg; riltozinamÉran 15mcg